AEVA vs ASML

AEVA's deterministic health scores signal severe financial distress: the Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score (with a Debt/Equity ratio of 7.75) raises significant bankruptcy risk. Despite strong revenue growth of 108.5% YoY, the company operates at a massive loss, with negative margins across all key metrics and a negative ROE of -258.39%. Insider selling totaling $22.37M over six months, including large sales by top executives, reinforces bearish sentiment. Although analysts rate it 'strong_buy' with a target of $24.10, the current price of $15.16 reflects a 5-year decline of 81.2%, suggesting deep skepticism from the market.

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.